BioNTech co-founders set to launch new mRNA venture as company sharpens oncology focus

Proactive

Tue, March 10, 2026 astatine 10:53 AM CDT 1 min read

BioNTech SE (NASDAQ:BNTX) co-founders Ugur Sahin and Özlem Türeci program to motorboat a caller autarkic biotech institution focused connected next-generation mRNA technologies, the German vaccine developer said connected Tuesday, arsenic it intensifies its absorption connected oncology.

BioNTech said it volition lend definite related rights and technologies to the caller task successful speech for a number stake, with imaginable milestone payments and royalties.

The institution stressed that its existent pipeline remains unchanged, and it inactive expects to person 15 ongoing Phase 3 oncology trials by the extremity of 2026. The co-founders are expected to modulation to the caller institution by year-end.

The announcement weighed connected BioNTech shares, which fell 21% successful aboriginal trading.

In a abstracted filing, BioNTech reported a nett nonaccomplishment of €1.14 cardinal ($1.33 billion) for 2025, compared with a nonaccomplishment of €665 cardinal successful 2024.

Despite continued concern successful caller cause development, the institution ended 2025 with €17.2 cardinal successful currency and fiscal securities, mostly supported by the commercialized occurrence of its COVID-19 vaccine.